{
    "id": 5525,
    "name": "anal squamous cell carcinoma",
    "source": "DOID",
    "definition": "An anal carcinoma that arises near the squamocolumnar junction. [url:http\\://en.wikipedia.org/wiki/Anal_cancer]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5525",
    "evidence": [
        {
            "id": 12611,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Prexasertib (LY2606368) treatment resulted in partial response in a patient with anal squamous cell carcinoma (PMID: 27044938).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1651,
                "therapyName": "Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5525,
                "name": "anal squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10479,
                    "pubMedId": 27044938,
                    "title": "Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27044938"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14564,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, treatment with Prexasertib (LY2606368) resulted in an overall response rate of 15% (4/26; 1 complete response (CR) and 3 partial responses (PR)), a clinical benefit rate (CR+PR+stable disease) of 58% (15/26), and a median progression-free survival of 2.8 months in patients with squamous cell carcinoma of the anus (PMID: 29643063; NCT0115790).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1651,
                "therapyName": "Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 5525,
                "name": "anal squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11752,
                    "pubMedId": 29643063,
                    "title": "Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29643063"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00316888",
            "title": "Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1928,
                    "therapyName": "Cetuximab + Cisplatin + Fluorouracil + Radiotherapy",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03357757",
            "title": "Avelumab With Valproic Acid in Virus-associated Cancer (LATENT)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6769,
                    "therapyName": "Avelumab + Valproic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03386500",
            "title": "Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5829,
                    "therapyName": "BMX-001",
                    "synonyms": null
                }
            ]
        }
    ]
}